ALX Oncology : ASPEN-06 Phase 2 Interim Gastric/GEJ Cancer Data Conference Call
October 03, 2023 at 12:07 pm EDT
Share
ASPEN-06
Phase 2 Interim
Gastric/GEJ Cancer Data
Conference Call
October 03, 2023
Forward-looking statements
Certain information set forth in this presentation contains "forward-looking information", under applicable laws collectively referred to herein as forward-looking statements. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to the (i) results and cost and timing of our product development activities and clinical trials; (ii) completion of the Company's clinical trials that are currently underway, in development or otherwise under consideration; (iii) our expectations about the timing of achieving regulatory approval and the cost of our development programs;
projected financial performance of the Company; (v) the expected development of the Company's business, projects, collaborations and joint ventures; (vi) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (vii) sources and availability of third-party financing for the Company's research and development; (viii) future liquidity, working capital, and capital requirements; and (ix) industry trends. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Report on Form 10-K and other documents ALX Oncology files with the SEC from time to time.
Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
This presentation also contains estimates and other statistical data made by independent parties and by ALX Oncology relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of ALX Oncology's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.
1
ALX Oncology program update call
Welcome
Evorpacept program overview
Gastric/GEJ cancer overview
ASPEN-06
Prespecified interim analysis
Closing remarks
Jason Lettmann
CEO, ALX Oncology
Dr. Sophia Randolph, MD, PhD
CMO, ALX Oncology
AGENDA
Dr. Josep Tabernero, MD, PhD
Chief of Medical Oncology,
Vall d'Hebron University Hospital,
Barcelona, Spain
Jason Lettmann
CEO, ALX Oncology
2
Evorpacept: A first-in-class approach to targeting CD47
SIRPαCD47
Macrophage
Don't eat me
Cancer cell
Eat me
Fc receptor
Anti-cancer drug
Target cells overexpress CD47 to evade destruction by macrophages
High affinity CD47 binding domains of SIRPα
Inactive
Fc domain
Evorpacept
A differentiated CD47 blocker
3
Evorpacept targets the CD47 checkpoint
Dendritic cell
Macrophage
Cancer cell
Fc receptor
Evorpacept (ALX148)
Fc receptor
Macrophage
Red
blood
SIRPα
CD47
cell
Complete CD47 blockade
without targeting blood cells
Macrophage
Anti-cancer antibody
Cancer cell
Evorpacept (ALX148)
Macrophage
Red
blood
cell
Combined with cancer therapy to
specifically target cancer cells
4
Attachments
Original Link
Original Document
Permalink
Disclaimer
ALX Oncology Holdings Inc. published this content on 03 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2023 16:06:31 UTC.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a donât eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.